Impact of family history on clinicopathological variables and disease progression in Japanese prostate cancer patients undergoing robotic‐assisted radical prostatectomy

<jats:sec><jats:title>Objective</jats:title><jats:p>We evaluated whether a first‐degree family history (FH) of prostate cancer (PCa) in Japanese patients undergoing robotic‐assisted radical prostatectomy (RP) is correlated with clinicopathological variables and disease progression.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We reviewed consecutive 392 localized PCa patients undergoing robotic‐assisted RP at our institution between 2015 and 2020. Information on FH was obtained via a self‐administered questionnaire. A positive FH was defined as having a first‐degree FH: a father and/or one or more brothers with PCa prior to diagnosis. All patients had clinically localized PCa treated by robotic‐assisted RP. We evaluated the relationship between clinical characteristics, pathological findings, and biochemical progression‐free survival (bPFS) according to first‐degree FH status.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Median follow‐up was 20.8 months. FH was identified in 42 (10.7%) patients. Patients in the FH group (median, 64.8 years) were diagnosed at a significantly younger age than patients in the non‐FH (NFH) group (patients without FH) (median, 67.7 years) (<jats:italic>p</jats:italic> = 0.003). The 5‐year bPFS in the FH and NFH groups was 72.0% and 78.1%, respectively (<jats:italic>p</jats:italic> = 0.90). A subgroup analysis revealed a significant difference in prostate‐specific antigen (PSA) density between the FH group (median, 0.51 ng/ml/cm<jats:sup>3</jats:sup>) and the NFH group (median, 0.29 ng/ml/cm<jats:sup>3</jats:sup>) in patients younger than 60 years (<jats:italic>p</jats:italic> = 0.033).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>In this RP population, FH of PCa was not associated with worse clinical characteristics, pathological findings, or disease progression. Patients with a FH underwent surgery at a significantly younger age, and among patients <60 years, patients with a FH had significantly higher PSA density compared with patients without a FH.</jats:p></jats:sec>